In particular, when used in conjunction with immune checkpoint inhibitors (ICIs) and Stimulator of Interferon Genes (STING) agonists, lactate inhibitors can significantly decrease tumor immunosuppression and promote the activation of tumor-infiltrating T cells [228, 229]. The gene discussed is STING1; the disease is neoplasm.